Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
In memoriam: Howard Fields, pain research pioneer
Over six decades, Fields mapped out the circuits of both pain and addiction.
In memoriam: Howard Fields, pain research pioneer
Over six decades, Fields mapped out the circuits of both pain and addiction.
Still no proof for facilitated spelling methods
A systematic review into whether the “rapid prompting method” or “spelling to communicate” can help autistic people express themselves comes up empty yet again.
Still no proof for facilitated spelling methods
A systematic review into whether the “rapid prompting method” or “spelling to communicate” can help autistic people express themselves comes up empty yet again.
Oregon primate center scientists fight proposed sanctuary transition
A group of employees has launched a series of campaigns to advocate for their work and argue against the center’s potential transition to an animal sanctuary.
Oregon primate center scientists fight proposed sanctuary transition
A group of employees has launched a series of campaigns to advocate for their work and argue against the center’s potential transition to an animal sanctuary.